Back to search

Article

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances the Antitumoral Activity of Gemcitabine in Human Pancreatic Cancer Cell Lines

2014-01-01

Abstract excerpt

Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most common malignant tumors still associated with poor prognosis in advanced stages. Gemcitabine is one of the standard agents for the treatment of PDAC, without having a major impact on the clinical outcome. Combining two compounds acting via different ways of action may result in a better efficacy. Methods: We investigated the effects of gemc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
39fa242e-a23c-58a6-8885-158211c6798c
DOI
10.4172/2329-6771.1000133
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances the Antitumoral Activity of Gemcitabine in Human Pancreatic Cancer Cell LinesDOI 10.4172/2329-6771.1000133
Select a neighboring publication to make it the new centre.